Inve US ▾
IMIMVT

Immunovant (IMVT) Q1 FY27 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q1 FY27)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

Immunovant Q1 FY27 — Busy Pipeline Ahead of Key Readouts and Launch

Immunovant reported a quiet quarter, but highlighted significant upcoming catalysts, including the imminent potential launch of brexpiprazole in dermatomyositis. The company is preparing for a "jampacked second half" with multiple top-line data readouts and program updates across its pipeline, including NIU, PH-ILD, and DroTRA. Management emphasized a "slow and steady" launch approach for brexpiprazole DM to build a strong foundation for future indications, while also progressing litigation and capital return initiatives.

Highlights

4

  • Brexpiprazole Phase III study in cutaneous sarcoidosis initiated ahead of schedule, following positive Phase II data showing a >20-point benefit on the CSAMI scale.

  • Initial $950 million payment from Moderna settlement received, with approximately $770 million allocated to Genevant.

  • Significant share repurchase activity, with about $200 million executed in the quarter at an average price in the high $20s.

  • Brexpiprazole DM launch is on track for imminent potential approval and launch by the end of September.

Concerns

3

  • Lack of clear signal on 6-minute walk distance in PH-ILD study

  • Variability in placebo response rates in NIU Phase III study

  • Physician concerns about JAK class safety profile for Brexpiprazole

Guidance & targets

CategoryTargetConfidence
Brexpiprazole launch in dermatomyositis (DM)
Expected launch
high materiality
High
Brexpiprazole NIU study top-line data
Top-line data readout
high materiality
High
Mosely (PH-ILD) Phase III study top-line data
Top-line data readout
high materiality
High
DroTRA program updates (Immunovant)
Updates including FDA conversation and study results
medium materiality
High
POC study in CLE top-line data
Top-line data readout
low materiality
High
Brexpiprazole cutaneous sarcoidosis (CS) Phase III top-line data
Top-line data readout
medium materiality
High
Overall catalyst calendar
3+ commercial launches, 9 study readouts, 4+ NDA/BLA filings, number of proof-of-concept studies
high materiality
High

Deals & partnerships

Moderna Patent infringement settlement $950 million

Initial payment received from the settlement.

Pfizer and BioNTech Patent infringement litigation $1.3 billion

Filed 3 international lawsuits in July (Canada and UPC).

Risks & headwinds

Lack of clear signal on 6-minute walk distance in PH-ILD study H2 FY27

not powered for 6-minute walk

Mitigation:Study designed with emphysema in mind; focus on PVR signal as primary indicator of benefit.

Variability in placebo response rates in NIU Phase III study H2 FY27

we don't know exactly what placebo response rates will be in that study

Mitigation:Phase II data was compelling, indicating high drug activity; geographic variation is a known feature of immunology studies.

Physician concerns about JAK class safety profile for Brexpiprazole Near-term (launch)

JAK class safety concerns

Mitigation:DM patients have high unmet need and are often on therapies (e.g., high-dose steroids) with worse safety concerns; physicians are generally comfortable using JAKs in this context.

What to watch in Q2 FY27

Brexpiprazole DM launch

Q3 FY27 (by end of September)
Current PDUFA date this quarter, launch expected by end of September
Target Approval and commercial launch

Why it matters

First commercial launch for a targeted therapy in dermatomyositis, critical for establishing market presence and future growth.

brexpiprazole expected to launch by the end of September.

Find out whether IMVT delivers this. Inve re-checks your case every morning.

Q&A highlights

What metrics will be provided for the DM launch? Are there implications of sotatercept use in PH-ILD for 6-minute walk and PVR?

The company will not provide extensive early metrics for the DM launch, focusing on internal understanding. For PH-ILD, the study was designed considering emphysema, and vasodilation is expected to drive benefit. A clear PVR signal is anticipated, but the study is not powered for 6-minute walk distance.

“I don't know that we're going to provide a ton of detail in the early days. I think it's important for us mostly to spend our time focused on understanding those dynamics ourselves, getting out, talking to patients, talking to physicians, doing the work we need to do.”

asked by Lut Ming Cheng · answered by Matthew Gline

2 min read 5 chapters

Detailed narrative

Brexpiprazole DM Launch Strategy

Management outlined a "slow and steady" approach for the brexpiprazole launch in dermatomyositis (DM), expected by the end of September. This strategy prioritizes building a strong foundation around patient access, support, and scientific communication over rapid initial uptake. The goal is to maximize the long-term opportunity for brexpiprazole across its multiple potential indications, including non-infectious uveitis (NIU), cutaneous sarcoidosis (CS), and lichen planopilaris (LPP).

Pipeline Progress and Upcoming Catalysts

The company anticipates a "jampacked second half" of 2026, with several key data readouts. These include top-line data for brexpiprazole in NIU, Mosely (PH-ILD) Phase III data, and proof-of-concept data for brexpiprazole in cutaneous lupus erythematosus (CLE). Additionally, updates on the DroTRA program, including an FDA conversation and study results, are expected. The Phase III study for brexpiprazole in cutaneous sarcoidosis has already begun enrolling patients, with top-line data anticipated in 2028.

Moderna Settlement and Litigation Update

Immunovant has received the initial $950 million payment from the Moderna settlement, with approximately $770 million directed to Genevant. The company is also actively pursuing litigation against Pfizer and BioNTech, having filed three international lawsuits in July, with a potential for an additional $1.3 billion if a favorable outcome is achieved in the '498 part of the case.

Financial Highlights and Capital Allocation

For Q1 FY27, the company reported approximately $200 million in R&D expense, under $100 million in non-GAAP adjusted G&A, and $166 million in GAAP G&A. Cash and investments stood at just under $4 billion before the Moderna settlement payment. Following the settlement, the company accelerated its share repurchase program, buying back about $200 million in the quarter at an average price in the high $20s, and plans to continue repurchases under existing authorizations.

Brexpiprazole in Cutaneous Sarcoidosis (CS)

The Phase III study for brexpiprazole in cutaneous sarcoidosis has commenced enrollment ahead of schedule. The study is designed for 140 patients, randomized 3:2 to 45mg brexpiprazole or placebo over 16 weeks, with a mandatory steroid taper. The primary endpoint is a ≥50% response rate on the CSAMI scale, building on Phase II data that showed a >20-point benefit compared to placebo, exceeding the clinical meaningfulness goal of a 5-point benefit.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.